Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.180
-0.010 (-0.31%)
Jul 10, 2026, 4:00 PM EDT - Market closed

Esperion Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
819907431353465304
Market Cap Growth
309.32%110.57%21.91%-23.92%52.62%-54.83%
Enterprise Value
1,207991.68583.72537.37558.66305.26
Last Close Price
3.183.702.202.996.235.00
Forward PE
-12.2616.60---
PS Ratio
1.962.251.303.046.163.88
PB Ratio
--3.00-1.11-0.78-1.43-1.55
EV/Sales Ratio
2.892.461.764.627.403.89
EV/EBITDA Ratio
15.9116.4210.72---
EV/EBIT Ratio
15.9316.4510.73---
Debt / Equity Ratio
-0.81-0.83-0.76-0.58-0.80-1.31
Debt / EBITDA Ratio
3.334.185.46---
Net Debt / Equity Ratio
-0.31-0.28-0.39-0.40-0.290.00
Net Debt / EBITDA Ratio
1.271.402.81-1.18-0.530.00
Net Debt / FCF Ratio
-5.25-6.44-6.38-1.36-0.540.00
Asset Turnover
0.901.001.210.510.240.21
Inventory Turnover
1.261.290.860.860.770.56
Quick Ratio
0.961.020.910.842.173.85
Current Ratio
1.531.541.371.292.674.48
Return on Equity (ROE)
1.83%6.57%12.27%53.74%89.74%183.64%
Return on Assets (ROA)
16.33%16.20%19.80%-68.57%-57.03%-61.71%
Return on Invested Capital (ROIC)
46.32%49.95%73.94%-151.62%-77.39%-79.92%
Return on Capital Employed (ROCE)
46.32%45.89%73.94%-151.62%-77.39%-79.92%
Buyback Yield / Dilution
-14.32%-11.05%-81.54%-55.26%-129.76%-5.20%
Total Shareholder Return
-14.32%-11.05%-81.54%-55.26%-129.76%-5.20%
SEC Filings: 10-K · 10-Q